Point72 Asia (Singapore) Pte. Ltd. Aadi Bioscience, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $379 Billion
- Q4 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 11,609 shares of AADI stock, worth $30,067. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,609
Previous 12,121
4.22%
Holding current value
$30,067
Previous $25 Million
46.69%
% of portfolio
0.01%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AADI
# of Institutions
57Shares Held
15.6MCall Options Held
15KPut Options Held
3.1K-
Avoro Capital Advisors LLC New York, NY2.85MShares$7.38 Million0.13% of portfolio
-
Qvt Financial LP New York, NY2.31MShares$5.99 Million0.72% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2.1MShares$5.44 Million4.12% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$4.79 Million8.31% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.15MShares$2.97 Million1.96% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $54.4M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...